Protalix BioTherapeutics Announces Completion Of Enrollment For Its Pivotal Phase III Clinical Trial Of Gaucher Disease

Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans. “The completion of enrollment signifies that we are one important step closer to our goal of commercializing prGCD,” said Dr.

More: continued here

Filed under: Clinical Trials on December 5th, 2008